BACKGROUND: Radiofrequency ablation (RFA) is minimally invasive and can achieve a high rate of cure of liver cancer. This study was conducted to evaluate the efficacy and safety of a bipolar RFA device (CelonPOWER System) in the treatment of Japanese liver cancer patients. METHODS: The study was a multicenter, single-group, open-label trial. The indications for RFA were based on the Japanese guidelines for the management of liver cancer. The subjects had a Child-Pugh classification of A or B, and the target tumors were defined as nodular, numbering up to 3 lesions, each of which was 3 cm or less in diameter, or solitary lesions up to 4 cm in diameter. To test for the non-inferiority of the CelonPOWER System, this system was compared with the Cool-tip RF System, which has already been approved in Japan, in terms of the complete necrosis rate (CNR). RESULTS: The CNR obtained with the CelonPOWER System was 97.8 % (88/90 patients). The CNR obtained with the Cool-tip RF System was 86.2 % (50/58 patients), confirming the non-inferiority of the CelonPOWER System (p < 0.001, Fisher's exact test based on binomial distribution). Throughout the treatment and follow-up periods, there were no adverse events regarding safety that were uniquely related to the CelonPOWER System and there were no cases of device failure. CONCLUSIONS: The CelonPOWER System was confirmed to be an effective and safe RFA device. It could become extensively used as a safe next-generation RFA device, reducing the physical burden on patients.
BACKGROUND: Radiofrequency ablation (RFA) is minimally invasive and can achieve a high rate of cure of liver cancer. This study was conducted to evaluate the efficacy and safety of a bipolar RFA device (CelonPOWER System) in the treatment of Japanese liver cancerpatients. METHODS: The study was a multicenter, single-group, open-label trial. The indications for RFA were based on the Japanese guidelines for the management of liver cancer. The subjects had a Child-Pugh classification of A or B, and the target tumors were defined as nodular, numbering up to 3 lesions, each of which was 3 cm or less in diameter, or solitary lesions up to 4 cm in diameter. To test for the non-inferiority of the CelonPOWER System, this system was compared with the Cool-tip RF System, which has already been approved in Japan, in terms of the complete necrosis rate (CNR). RESULTS: The CNR obtained with the CelonPOWER System was 97.8 % (88/90 patients). The CNR obtained with the Cool-tip RF System was 86.2 % (50/58 patients), confirming the non-inferiority of the CelonPOWER System (p < 0.001, Fisher's exact test based on binomial distribution). Throughout the treatment and follow-up periods, there were no adverse events regarding safety that were uniquely related to the CelonPOWER System and there were no cases of device failure. CONCLUSIONS: The CelonPOWER System was confirmed to be an effective and safe RFA device. It could become extensively used as a safe next-generation RFA device, reducing the physical burden on patients.
Authors: Stephan Clasen; Diethard Schmidt; Klaus Dietz; Andreas Boss; Stefan M Kröber; Christina Schraml; Jan Fritz; Claus D Claussen; Philippe L Pereira Journal: Invest Radiol Date: 2007-01 Impact factor: 6.016
Authors: Liesbeth M Veenendaal; Inne H M Borel Rinkes; Richard van Hillegersberg Journal: Eur J Gastroenterol Hepatol Date: 2006-01 Impact factor: 2.566
Authors: Joerg-Peter Ritz; Kai S Lehmann; Christoph Reissfelder; Thomas Albrecht; Bernd Frericks; Urte Zurbuchen; Heinz J Buhr Journal: Int J Colorectal Dis Date: 2005-05-05 Impact factor: 2.571
Authors: Won Chang; Jeong Min Lee; Jeong Hee Yoon; Dong Ho Lee; Sang Min Lee; Kyoung Bun Lee; Bo Ram Kim; Tae-Hyung Kim; Seunghyun Lee; Joon Koo Han Journal: PLoS One Date: 2017-04-26 Impact factor: 3.240